rather than training workers to enhance innovation performance. …

pharma should either build a critical mass of disease area knowledge or diversify projects over different DA’s in order to … obtain higher success probabilities. Projects in which a firm has built a critical mass of disease knowledge (through at … interpret this finding as knowledge spillovers from external to internal projects, as the limited number of external projects …

innovation. We develop a formal model of an innovation arising from the combination of two existing modules with the objective to … innovation) and the benefits associated with returns to scale. We derive conditions for optimal diversity under different regimes …

firms because it lowers the probability they win the innovation contest for that project; however, the investment of a firm …

effect of recombinant innovation of the two technologies. A mechanism of endogenous competition is described involving a … positive externality of increasing returns to investment which are counterbalanced by recombinant innovation. We determine … innovation. …

framework and a test on innovation data from several European cities. This framework is mainly built on the product life …

rival market. We show that this strategic effect dominates the usual "innovation for buyout effect" when the entrant …'s bargaining power is below a threshold. Allowing for acquisitions may improve the direction of innovation of each of the players …